Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia

National Center for Research Resources (NCRR)60 enrolled

Overview

OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia. II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.

PROTOCOL OUTLINE: This is a randomized study. One group of patients is treated with soy protein isolate for 12 weeks. The control group receives a placebo for 12 weeks. Patients cross to the alternate group following a 4-week washout.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Enrollment

Conditions

Hereditary Hemorrhagic Telangiectasia

Interventions

soy protein isolateDRUG

Eligibility

Sex: ALLMin age: 15 Years

Medical Language ↔ Plain English

* Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following: * First-degree relative with HHT * History of recurrent epistaxis or gastrointestinal bleeding * Three or more skin telangiectasia * Migraine headache meeting International Headache Society criteria 3 or more times a month for more than 1 year * No pattern of daily headaches * No severe head trauma * No onset of headaches after 50 years of age * At least 1 month since migraine prophylaxis * At least 1 month since any of the following medications: Beta blockers; Calcium channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin re-uptake inhibitors * Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed * Creatinine no greater than 2.5 g/dL * No allergy to soy * No pregnant women * No women with intent to become pregnant

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.